葵花药业：10月27日召开董事会会议

Core Viewpoint - Kew Flower Pharmaceutical announced the convening of its fifth board meeting to review the third quarter report for 2025, indicating ongoing corporate governance and financial oversight [1] Company Summary - Kew Flower Pharmaceutical's revenue composition for the first half of 2025 shows that the pharmaceutical industry accounts for 99.61% of its total revenue, while other businesses contribute only 0.39% [1] - As of the report, Kew Flower Pharmaceutical has a market capitalization of 9.1 billion yuan [1]